Farbod Shojaei

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi Anti-angiogenesis therapy in cancer: current challenges and future perspectives
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:130-7. 2012
  2. doi HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:48-55. 2012
  3. doi HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
    Farbod Shojaei
    Oncology Research Unit, Pfizer, La Jolla, California, USA
    Cancer Res 70:10090-100. 2010
  4. doi Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice
    Brett H Simmons
    Oncology Research Unit, Pfizer Global R and D, San Diego, CA 92121, USA
    Cancer Chemother Pharmacol 70:213-20. 2012
  5. pmc Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer
    Farbod Shojaei
    Pfizer Global Research and Development, Department of Oncology, La Jolla, CA, USA
    J Exp Clin Cancer Res 31:26. 2012

Collaborators

  • Brett H Simmons
  • Anthony Wong
  • Kush Lalwani
  • Brittany A Snider
  • Patrick B Lappin
  • Jeetendra Eswaraka
  • James G Christensen
  • Anand Giddabasappa
  • Julie L Kan
  • Joseph H Lee

Detail Information

Publications5

  1. doi Anti-angiogenesis therapy in cancer: current challenges and future perspectives
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:130-7. 2012
    ..Investigations in clinic and preclinical models have provided some molecular and cellular mechanisms for the above challenges. This review aims to provide a concise update from recent findings...
  2. doi HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:48-55. 2012
    ..In conclusion, our findings indicate that sunitinib-induced metastasis is tumor cell-type dependent and further supports a rationale for combination of anti-angiogenics and c-Met inhibition in the clinic...
  3. doi HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
    Farbod Shojaei
    Oncology Research Unit, Pfizer, La Jolla, California, USA
    Cancer Res 70:10090-100. 2010
    ....
  4. doi Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice
    Brett H Simmons
    Oncology Research Unit, Pfizer Global R and D, San Diego, CA 92121, USA
    Cancer Chemother Pharmacol 70:213-20. 2012
    ..In conclusion, our data suggest that PD-0325901 at doses below MTD is still a potent compound capable of tumor growth inhibition where Kras and/or PI3K are drivers of tumor growth and progression...
  5. pmc Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer
    Farbod Shojaei
    Pfizer Global Research and Development, Department of Oncology, La Jolla, CA, USA
    J Exp Clin Cancer Res 31:26. 2012
    ....